A clinical monitoring system for clozapine

Australasian Psychiatry

Volumn 14, Issue 2, 2006, Pages 156-168

  Castle, David ^a   Lambert, Tim ^b,c   Melbourne, Sue ^d   Cox, Andrew ^e   Boardman, Gaylene ^f,g   Fairest, Katherine ^f   Davy, Martin ^h   Goh, Joyce ⁱ   Kuluris, Bill ^j   Berk, Michael ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^d SUNSHINE HOSPITAL   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f WidWest AMHS   (Australia)

^g VICTORIA UNIVERSITY   (Australia)

^h Northern AMHS   (Australia)

ⁱ North Western Mental Health ^*  (Australia)

^j BARWON HEALTH   (Australia)

more..

Author keywords

Clinical monitoring system; Clozapine; Schizophrenia; Treatment resistance

Indexed keywords

ANTIBIOTIC AGENT; CARBAMAZEPINE; CARDIOVASCULAR AGENT; CHLORAMPHENICOL; CIPROFLOXACIN; CITALOPRAM; CLARITHROMYCIN; CLOZAPINE; COTRIMOXAZOLE; DIAZEPAM; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; KETOCONAZOLE; LAMOTRIGINE; LISINOPRIL; LITHIUM SALT; LORAZEPAM; MODAFINIL; MOOD STABILIZER; NEUROLEPTIC AGENT; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PSYCHOTROPIC AGENT; QUINIDINE; RIFABUTIN; RIFAMPICIN; UNINDEXED DRUG;

AGRANULOCYTOSIS; ARTICLE; ATAXIA; BLOOD DYSCRASIA; BONE MARROW SUPPRESSION; CLINICAL PROTOCOL; COMMUNITY CARE; DISEASE RESISTANCE; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG SURVEILLANCE PROGRAM; GENERAL PRACTICE; HEART DISEASE; HUMAN; MEDICAL DOCUMENTATION; NEUROTOXICITY; PATIENT MONITORING; SALIVATION; SCHIZOPHRENIA; SEDATION; SIDE EFFECT;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOCUMENTATION; DRUG INTERACTIONS; DRUG MONITORING; DRUG RESISTANCE; HUMANS; LONGITUDINAL STUDIES; MEDICAL RECORDS, PROBLEM-ORIENTED; MONITORING, PHYSIOLOGIC; REFERRAL AND CONSULTATION; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 33748440763     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.1111/j.1440-1665.2006.02267.x     Document Type: Article

References (19)

1. Wagstaff AJ, Bryson HM. Clozapine? CNS Drugs 1995; 4: 370-400.
2. Castle DJ, Alderton D. Psychopharmacological management of schizophrenia. In: Castle DJ, Copolov DL, Wykes T, eds. Pharmacological and Psychosocial Treatments in Schizophrenia. London: Martin Dunitz, 2003: 1-22.
3. Fitzsimons J, Berk M, Lambert T, Bourin M, Dodd S. A review of clozapine safety. Expert Opinion on Drug Safety 2005; 4: 731-744.
4. Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. Journal of Clinical Psychiatry 2003; 64: 575-579.
5. Coodin S. Body mass index in persons with schizophrenia. Canadian Journal of Psychiatry 2001; 46: 549-555.
6. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychological Medicine 1999; 29: 697-701.
7. Allison DB, Mentore JL, Heo M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 1999; 156: 1686-1696.
8. George TP, Vessichio JC, Termine A. Nicotine and tobacco use in schizophrenia. In: Meyer JM, Nasrallah HA, eds. Medical Illness in Schizophrenia. Washington, DC: American Psychiatric Publishing, 2003: 81-98.
9. Henderson DC, Cagliero E, Gray C et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five year naturalistisc study. American Journal of Psychiatry 2000; 157: 975-981.
10. Meyer JM. Effects of atypical antipsychotics on weight gain and serum lipids. Journal of Clinical Psychiatry 2001; 62 (suppl. 27): 27-34.
11. Meyer JM. Cardiovascular illness and hyperlidemia in patients with schizophrenia. In: Meyer JM, Nasrallah HA, eds. Medical Illness in Schizophrenia. Washington, DC: American Psychiatric Publishing, 2003: 53-80.
12. Henderson DC, Ettinger EP. Glucose intolerance and diabetes in schizophrenia. In: Meyer JM, Nasrallah HA, eds. Medical Illness in Schizophrenia. Washington, DC: American Psychiatric Publishing, 2003: 99-114.
13. Lambert TJ, Chapman LH (on behalf of the consensus development group). Diabetes, psychotic disorders and antipsychotic therapy: A consensus statement. Medical Journal of Australia 2004; 181: 544-548.
14. Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. Journal of Clinical Psychopharmacology 2005; 25: 32-41.
15. Bochner F, Allardice J, Ames D et al. Therapeutic Guidelines: Psychotropic, Version 5. Melbourne: Therapeutic Guidelines, 2003.
16. Bezchlibnyk-Butler KZ, ed. Clinical Handbook of Psychotropic Drugs, 14th edn. Toronto: Hogrefe and Huber, 2004.
17. Rossi S, ed. Australian Medicines Handbook. Adelaide: Australian Medicines Handbook, 2005.
18. Tatro DS, ed. Drug Interaction Facts. St Louis: Facts and Comparisons Publishing Group, 2003.
19. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry 2002; 63: 892-909.